Evaluation of Immune Dysregulation in an Austrian Patient Cohort Suffering from Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.
Lutz, Lena, Rohrhofer, Johanna, Zehetmayer, Sonja et al. · Biomolecules · 2021 · DOI
Quick Summary
This study looked at blood test results from 262 ME/CFS patients to understand problems with their immune systems. Researchers found that nearly two-thirds of patients had low levels of certain immune proteins or cells, while about one-quarter showed signs of inflammation. These findings suggest that immune system dysfunction is a common feature of ME/CFS and could potentially be used to help diagnose or treat the condition.
Why It Matters
This study provides objective immunological evidence supporting the biological basis of ME/CFS, demonstrating that immune dysfunction is present in the majority of patients. These findings could inform future diagnostic criteria and targeted therapeutic strategies for ME/CFS, shifting the disease from being viewed primarily as psychiatric toward recognition of underlying physiological abnormalities.
Observed Findings
64.9% of ME/CFS patients had reduction or deficiency in at least one immune parameter
26.3% of patients showed signs of immune activation or inflammation
17.6% of patients had unclassified antibody deficiency, with IgG3 and IgG4 subclass deficiencies being most common
32% of patients had reduced MBL levels, with 7% showing complete MBL deficiency
39% overall had MBL abnormalities (reduced or deficient levels combined)
Inferred Conclusions
Immune dysfunction is a fundamental feature of ME/CFS, present in the majority of patients studied
Immune parameters may serve as disease biomarkers and could enable targeted therapeutic interventions
The high prevalence of IgG subclass and MBL abnormalities warrants further investigation of complement pathway dysfunction in ME/CFS
Remaining Questions
Do these immune abnormalities differ between ME/CFS severity grades and does correction of deficiencies improve clinical outcomes?
Which immune dysfunctions are disease-causing versus secondary to chronic illness, and do these patterns remain stable longitudinally?
What This Study Does Not Prove
This study does not establish causation or prove that immune dysfunction causes ME/CFS symptoms—it only shows correlation in a single patient population. It does not identify whether immune changes are primary disease mechanisms or secondary consequences of illness. The lack of healthy control comparison and longitudinal follow-up prevents determination of whether these immune patterns are stable biomarkers or fluctuate over time.
How do these Austrian patient findings generalize to other geographic populations, and what genetic or environmental factors explain the heterogeneity of immune phenotypes?
Do specific immune profiles correlate with particular symptom clusters or predict treatment response to immune-targeting therapies?